A Clinically Meaningful Fetal Hemoglobin Threshold for Children with Sickle Cell Anemia During Hydroxyurea Therapy

Por Estepp, Jeremie H., Smeltzer, Matthew P., Kang, Guolian, Li, Chen, Wang, Winfred C., Abrams, Christina, Aygun, Banu, Ware, Russell E., Nottage, Kerri, Hankins, Jane S.
Publicado no Am J Hematol (2017)

Hydroxycarbamide in children with sickle cell anaemia after first‐dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure

Por Estepp, Jeremie H., Wiczling, Paweł, Moen, Joseph, Kang, Guolian, Mack, Joana Marie, Liem, Robert, Panepinto, Julie A., Garg, Uttam, Kearns, Gregory, Neville, Kathleen A.
Publicado no Br J Clin Pharmacol (2017)

Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease

Por Gammal, Roseann S., Crews, Kristine R., Haidar, Cyrine E., Hoffman, James M., Baker, Donald K., Barker, Patricia J., Estepp, Jeremie H., Pei, Deqing, Broeckel, Ulrich, Wang, Winfred, Weiss, Mitchell J., Relling, Mary V., Hankins, Jane
Publicado no Pediatrics (2016)

Pharmacokinetics and Bioequivalence of a Liquid Formulation of Hydroxyurea in Children With Sickle Cell Anemia

Por Estepp, Jeremie H., Melloni, Chiara, Thornburg, Courtney D., Wiczling, Paweł, Rogers, Zora, Rothman, Jennifer A., Green, Nancy S., Liem, Robert, Brandow, Amanda M., Crary, Shelley E., Howard, Thomas H., Morris, Maurine H., Lewandowski, Andrew, Garg, Uttam, Jusko, William J., Neville, Kathleen A.
Publicado no J Clin Pharmacol (2015)